The Global Gene Delivery Technologies Market is projected to reach $9.77 billion by 2028, from a value of $3.62 billion in 2022, by registering a CAGR of 18.0% during the forecast period. Advantages like briefness and nontoxicity nature, technological advancements in viral vectors, growing pipeline of advanced therapies, are the factors driving the market growth. However, several clinical challenges associated with viral systems have spurred the usage of chemical methods which may restrain the growth of the market. Moreover, rising success rates of novel medicines and ethical acceptability of gene therapy for cancer treatment are creating ample opportunities across the globe.
Recent Developments
In September 2021, Adaptimmune partnered with Genentech to develop allogeneic cell therapies indicated for multiple cancers. This partnership broadens Adaptimmune’s leadership position in developing allogeneic cell therapies building in-depth knowledge gained from autologous clinical programs.
In June 2021, Eisai and Bristol Myers Squibb agreed to collaborate on the development and commercialization of Eisai’s ADC, MORAb-202, for advanced solid malignancies.
In June 2021, GSK and iTeos Therapeutics collaborated to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies.
In May 2020, Merck announced the acquisition of Themis, a vaccines and immune-modulation therapies developer to expand its vaccine development capabilities for the SARS-CoV-2 vaccine program.
In May 2019, Thermo Fisher Scientific acquired Brammer Bio, a CDMO actively engaged in manufacturing viral vectors for gene therapies.
Competitive Landscape
Bio-Rad Laboratories, Inc., Catalent Inc., OriGene Technologies, Inc., Oxford Biomedica, Promega Corporation, QIAGEN, SignaGen Laboratories, Sirion-Biotech GmbH, System Biosciences llc, Takara Bio Inc., Thermo Fisher Scientific, Inc., Vectalys and Horizon Discovery Group Plc. are some of the major players in the global Gene Delivery Technologies market.
